Price-sensitive press releases
2023-03-09
STOCKHOLM, March 9[th], 2023, Moberg Pharma AB (OMX: MOB) today announces that Taisho Pharmaceutical Co., Ltd and Moberg Pharma terminate the license agreement for development, registration and commercialization of MOB-015 in Japan. Moberg Pharma regains full rights to the product in Japan and retains milestone revenues paid by Taisho.
2023-02-07
REGISTRATION PROCESS AND THE PHASE 3 STUDY ONGOING